Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prime Medicine, Inc. - Common Stock (NQ:PRME)

5.875 -0.205 (-3.37%)
Streaming Delayed Price Updated: 11:15 AM EDT, Oct 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prime Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Cathie Wood's Ark Invest Offloads Uipath, Prime Medicine, And Repare Therapeutics
On April 11th, 2025, Cathie Wood's Ark Invest sold shares in UiPath, Prime Medicine, and Repare Therapeutics, with notable gains and losses. 
Via Benzinga
Why Prime Medicine Stock Was Climbing Higher This Week
Via The Motley Fool
Why Prime Medicine Stock Is Soaring Today
Via The Motley Fool
Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
From Prime Medicine, Inc.
Via GlobeNewswire
Cathie Wood's Ark Invest Continues To Offload UiPath, Roblox: Loads Up On GitLab, Ibotta
Ark Invest's Cathie Wood-led funds made significant trades involving GitLab, Intellia, Prime Medicine, UiPath, Ibotta, Roblox, Repare Therapeutics, and CareDx. 
Via Benzinga
Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Participate in Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
12 High-Growth Stocks That Could Deliver Parabolic Returns
These 12 innovative companies could deliver exponential returns over the next quarter century. 
Via The Motley Fool
Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress
From Prime Medicine, Inc.
Via GlobeNewswire
Why I Keep Buying These 14 Incredible Growth Stocks
This diverse set of growth stocks offers tremendous opportunities in the fields of AI, space, biotech, and emerging industries. 
Via The Motley Fool
Topics Artificial Intelligence
Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings
From Prime Medicine, Inc.
Via GlobeNewswire
Why Prime Medicine Stock Soared Nearly 12% Higher on Monday
Changes are afoot at the company, and investors welcomed them. 
Via The Motley Fool
Dow Dips 300 Points; Emcore Shares Spike Higher
 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Crude Oil Moves Higher; Prime Medicine Shares Spike Higher
 
Via Benzinga
Prime Medicine, MINISO Group, Li Auto, Weibo And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
Prime Medicine enters a strategic collaboration with Bristol Myers Squibb to develop next-gen T-cell therapies, securing $110 million upfront with potential for $3.5 billion in milestones. The company... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Prime Medicine Unveils Strategically Focused Pipeline
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
From Prime Medicine, Inc.
Via GlobeNewswire
2 Growth Stocks That Could Make You Richer
Discover two cutting-edge growth stocks that could revolutionize medicine and space exploration. 
Via The Motley Fool
Prime Medicine to Participate in Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
PRME Stock Earnings: Prime Medicine Misses EPS for Q2 2024
PRME stock results show that Prime Medicine missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Present at Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names
Between FDA approvals and product pipelines, it takes diligence to keep up with which biotech stocks to buy. 
Via InvestorPlace
Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio
Alphabet may have strong insight into both company's industries. 
Via The Motley Fool
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.